US health officials fast-track coronavirus vaccine, hope to start clinical trial in three months [MSNBC.com]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: MSNBC.com
U.S. health officials are fast-tracking work on a coronavirus vaccine, hoping to start an early-stage trial within the next three months, the Trump administration said Tuesday. That timeline is optimistic, and a phase 1 trial does not mean "you have a vaccine that's ready for deployment," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, an agency within the Department of Health and Human Services. It could take a year or more before a vaccine is ready for sale to the public, he said. "It will take three months to get it into the trial, three months to get safety, immunogenicity data," Fauci said during a press briefing on the nation's response to the coronavirus, which has killed 106 people in mainland China and infected nearly 4,700 worldwide "Then you move into phase 2. What we do from that point on will be determined by what has happened with the outbreak over those months," he said. "We are proceeding as if we will have to deploy a vac
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive YearAccesswire
- Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.MarketBeat
- Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and OlderAccesswire
MRNA
Earnings
- 11/7/24 - Beat
MRNA
Sec Filings
- 11/12/24 - Form 4
- 11/12/24 - Form 144
- 11/7/24 - Form 10-Q
- MRNA's page on the SEC website